VIR
Vir Biotechnology, Inc.
Price Chart
Latest Quote
$9.40
-0.21 (-2.19%)
Current Price
| Previous Close | $9.61 |
| Open | $9.70 |
| Day High | $9.70 |
| Day Low | $9.12 |
| Volume | 1,921,555 |
Stock Information
| Shares Outstanding | 168.65M |
| Total Debt | $95.58M |
| Cash Equivalents | $476.30M |
| Revenue | $65.50M |
| Net Income | $-442.72M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $1.59B |
| EPS (TTM) | $-3.14 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $1.21B |
| Sales | $65.50M |
| Income | $-442.72M |
| Book/sh | $5.04 |
| Cash/sh | $2.82 |
| Employees | 367 |
Financial Ratios
| Quick Ratio | 6.52 |
| Current Ratio | 7.11 |
| Debt/Eq | 11.76 |
Returns & Margins
| ROA | -24.79% |
| ROE | -47.69% |
| Operating Margin | 459241.36% |
Ownership
| Insider Ownership | 6.59% |
| Institutional Ownership | 80.75% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -4.06 |
| P/S | 24.28 |
| P/B | 1.87 |
Analyst Data
| Recommendation | none |
| Target Price | $21.56 |
Technical Indicators
| SMA20 | $9.88 |
| SMA50 | $9.35 |
| SMA200 | $7.90 |
| RSI | 41.12 |
| ATR | 0.4884 |
| Shares Float | 128.76M |
| Short Float | 11.52% |
| Short Ratio | 8.17 |
| Volatility | 1.62 |
| Rel Volume | 0.73 |
Performance History
| Week | -5.32% |
| Month | +9.52% |
| Quarter | -8.71% |
| 6 Months | +38.27% |
| YTD | +58.75% |
| Year | +74.31% |
| 3 Years | -60.44% |
| 5 Years | -75.83% |
| 10 Years | -32.74% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-07-17 | $9.43 | 1,739,200 |
| 2026-07-16 | $9.40 | 1,955,000 |
| 2026-07-15 | $9.61 | 1,225,200 |
| 2026-07-14 | $9.49 | 1,675,900 |
| 2026-07-13 | $9.72 | 1,914,200 |
| 2026-07-10 | $9.96 | 1,676,700 |
| 2026-07-09 | $10.34 | 1,285,200 |
| 2026-07-08 | $10.43 | 1,951,900 |
| 2026-07-07 | $10.25 | 1,352,400 |
| 2026-07-06 | $10.02 | 1,569,800 |
| 2026-07-02 | $10.04 | 1,159,900 |
| 2026-07-01 | $9.56 | 1,905,100 |
| 2026-06-30 | $10.19 | 1,724,700 |
| 2026-06-29 | $10.38 | 1,935,000 |
| 2026-06-26 | $10.03 | 7,498,600 |
| 2026-06-25 | $9.88 | 1,337,000 |
| 2026-06-24 | $9.95 | 2,369,400 |
| 2026-06-23 | $10.16 | 2,534,000 |
| 2026-06-22 | $9.57 | 1,793,600 |
| 2026-06-18 | $9.16 | 8,795,000 |
About Vir Biotechnology, Inc.
Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors. The company's preclinical candidates include those targeting influenza A and B antibodies and antibody drug conjugates, and coronavirus monoclonal antibodies; and PRO-XTEN, a dual-masked TCEs targeting variety of solid tumors. It has grant collaboration and license agreement with Astellas; license agreement with Norgine for the treatment of CHD; amended and restated letter agreement with the Gates Foundation; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreement with the Institute for Research in Biomedicine; a license agreement with The Rockefeller University; license agreements with Xencor; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.
đ° Latest News
Is Vir Biotechnology, Inc. (VIR) A Good Stock To Buy Now?
Insider Monkey âĸ 2026-06-07T20:14:23Z
How SOLSTICE Phase 2 HDV Data at Vir Biotechnology (VIR) Has Changed Its Investment Story
Simply Wall St. âĸ 2026-05-24T14:13:19Z
Why a Biotech Fund Opened a New $6 Million Position in Vir Amid a 99% Stock Rally
Motley Fool âĸ 2026-05-23T22:33:51Z
Vir Biotechnology Stock Has Nearly Doubled in a Year. One Major Holder Just Trimmed $17 Million
Motley Fool âĸ 2026-05-18T15:19:55Z
Vir Biotechnology Stock Has Doubled This Past Year. One Fund Just Bought 1.2 Million Shares
Motley Fool âĸ 2026-05-17T20:07:57Z
Results: Vir Biotechnology, Inc. Delivered A Surprise Loss And Now Analysts Have New Forecasts
Simply Wall St. âĸ 2026-05-11T14:53:49Z
A Look At Vir Biotechnology (VIR) Valuation After The Astellas Partnership And Pipeline Progress
Simply Wall St. âĸ 2026-05-10T03:13:54Z
Vir Biotechnology's Chairman of the Board Sold 22,000 Company Shares. Here's What That Means for Investors.
Motley Fool âĸ 2026-05-09T14:06:01Z
Vir Biotechnology Q1 Earnings Call Highlights
MarketBeat âĸ 2026-05-07T08:18:18Z
Vir Biotechnology, Inc. Q1 2026 Earnings Call Summary
Moby âĸ 2026-05-07T00:23:44Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $26,000 | $845,000 | $2,765,000 | $146,319,000 |
| Cost Of Revenue | $26,000 | $845,000 | $2,765,000 | $146,319,000 |
| Total Revenue | $66,520,000 | $63,712,000 | $39,494,000 | $1,580,472,000 |
| Operating Revenue | $63,130,000 | $61,370,000 | $37,382,000 | $1,580,472,000 |
| Expenses | ||||
| Total Expenses | $546,030,000 | $615,882,000 | $710,240,000 | $747,404,000 |
| Other Income Expense | $1,502,000 | $-42,744,000 | $-44,438,000 | $-106,880,000 |
| Other Non Operating Income Expenses | $-409,000 | $-2,221,000 | $-8,991,000 | $4,260,000 |
| Net Non Operating Interest Income Expense | $40,238,000 | $71,809,000 | $86,990,000 | $28,092,000 |
| Operating Expense | $546,004,000 | $615,037,000 | $707,475,000 | $601,085,000 |
| Other Operating Expenses | $-2,036,000 | $-10,493,000 | $-46,686,000 | $-35,325,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-437,987,000 | $-521,960,000 | $-615,061,000 | $515,837,000 |
| Net Interest Income | $40,238,000 | $71,809,000 | $86,990,000 | $28,092,000 |
| Interest Income | $40,238,000 | $71,809,000 | $86,990,000 | $28,092,000 |
| Normalized Income | $-439,496,690 | $-481,518,046 | $-580,358,387 | $591,856,760 |
| Net Income From Continuing And Discontinued Operation | $-437,987,000 | $-521,960,000 | $-615,061,000 | $515,837,000 |
| Total Operating Income As Reported | $-479,328,000 | $-587,165,000 | $-684,305,000 | $833,068,000 |
| Net Income Common Stockholders | $-437,987,000 | $-521,960,000 | $-615,061,000 | $515,837,000 |
| Net Income | $-437,987,000 | $-521,960,000 | $-615,061,000 | $515,837,000 |
| Net Income Including Noncontrolling Interests | $-437,987,000 | $-521,960,000 | $-615,117,000 | $515,837,000 |
| Net Income Continuous Operations | $-437,987,000 | $-521,960,000 | $-615,117,000 | $515,837,000 |
| Pretax Income | $-437,770,000 | $-523,105,000 | $-628,194,000 | $754,280,000 |
| Special Income Charges | $182,000 | $-34,995,000 | $-13,559,000 | $0 |
| Interest Income Non Operating | $40,238,000 | $71,809,000 | $86,990,000 | $28,092,000 |
| Operating Income | $-479,510,000 | $-552,170,000 | $-670,746,000 | $833,068,000 |
| Gross Profit | $66,494,000 | $62,867,000 | $36,729,000 | $1,434,153,000 |
| Per Share | ||||
| Diluted EPS | $-3.16 | $-3.83 | $-4.59 | $3.83 |
| Basic EPS | $-3.16 | $-3.83 | $-4.59 | $3.89 |
| Other | ||||
| Tax Effect Of Unusual Items | $401,310 | $-81,046 | $-744,387 | $-35,120,240 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-469,741,000 | $-497,088,000 | $-615,848,000 | $950,991,000 |
| Total Unusual Items | $1,911,000 | $-40,523,000 | $-35,447,000 | $-111,140,000 |
| Total Unusual Items Excluding Goodwill | $1,911,000 | $-40,523,000 | $-35,447,000 | $-111,140,000 |
| Reconciled Depreciation | $11,680,000 | $14,559,000 | $19,451,000 | $6,783,000 |
| EBITDA (Bullshit earnings) | $-467,830,000 | $-537,611,000 | $-651,295,000 | $839,851,000 |
| EBIT | $-479,510,000 | $-552,170,000 | $-670,746,000 | $833,068,000 |
| Diluted Average Shares | $138,520,419 | $136,246,865 | $134,130,924 | $134,810,908 |
| Basic Average Shares | $138,520,419 | $136,246,865 | $134,130,924 | $132,606,767 |
| Diluted NI Availto Com Stockholders | $-437,987,000 | $-521,960,000 | $-615,061,000 | $515,837,000 |
| Minority Interests | $0 | $0 | $56,000 | $0 |
| Tax Provision | $217,000 | $-1,145,000 | $-13,077,000 | $238,443,000 |
| Restructuring And Mergern Acquisition | $-182,000 | $34,995,000 | $13,559,000 | $0 |
| Gain On Sale Of Security | $1,729,000 | $-5,528,000 | $-21,888,000 | $-111,140,000 |
| Research And Development | $455,966,000 | $506,499,000 | $579,720,000 | $474,648,000 |
| Selling General And Administration | $92,074,000 | $119,031,000 | $174,441,000 | $161,762,000 |
Fetched: 2026-07-17
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $740,489,000 | $1,125,328,000 | $1,550,707,000 | $2,028,302,000 |
| Total Assets | $1,002,823,000 | $1,398,813,000 | $1,919,060,000 | $2,802,088,000 |
| Total Non Current Assets | $488,743,000 | $356,355,000 | $330,861,000 | $282,980,000 |
| Other Non Current Assets | $31,662,000 | $18,420,000 | $18,857,000 | $21,226,000 |
| Investmentin Financial Assets | $314,575,000 | $190,015,000 | $105,275,000 | $23,927,000 |
| Goodwill And Other Intangible Assets | $24,787,000 | $25,057,000 | $39,529,000 | $49,661,000 |
| Other Intangible Assets | $7,850,000 | $8,120,000 | $22,592,000 | $32,724,000 |
| Current Assets | $514,080,000 | $1,042,458,000 | $1,588,226,000 | $2,519,077,000 |
| Other Current Assets | $45,143,000 | $47,725,000 | $52,549,000 | $104,356,000 |
| Restricted Cash | $1,922,000 | $89,385,000 | $13,268,000 | $12,681,000 |
| Cash Cash Equivalents And Short Term Investments | $467,015,000 | $905,348,000 | $1,522,409,000 | $2,402,040,000 |
| Cash And Cash Equivalents | $232,185,000 | $222,947,000 | $241,576,000 | $848,631,000 |
| Receivables | - | - | - | $0 |
| Prepaid Assets | - | - | - | - |
| Other Receivables | - | - | - | - |
| Debt | ||||
| Total Debt | $97,852,000 | $97,891,000 | $124,540,000 | $127,974,000 |
| Long Term Debt And Capital Lease Obligation | $89,054,000 | $90,139,000 | $111,673,000 | $123,837,000 |
| Current Debt And Capital Lease Obligation | $8,798,000 | $7,752,000 | $12,867,000 | $4,137,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $237,547,000 | $248,428,000 | $328,824,000 | $724,125,000 |
| Total Non Current Liabilities Net Minority Interest | $144,732,000 | $128,766,000 | $153,417,000 | $213,096,000 |
| Other Non Current Liabilities | $55,678,000 | $38,627,000 | $41,744,000 | $36,052,000 |
| Current Liabilities | $92,815,000 | $119,662,000 | $175,407,000 | $511,029,000 |
| Current Deferred Liabilities | $0 | $12,648,000 | $64,853,000 | $15,517,000 |
| Payables And Accrued Expenses | $84,017,000 | $83,202,000 | $97,687,000 | $491,375,000 |
| Payables | $11,628,000 | $16,670,000 | $15,536,000 | $29,302,000 |
| Other Payable | $1,825,000 | $11,589,000 | $9,202,000 | $7,652,000 |
| Accounts Payable | $9,803,000 | $5,081,000 | $6,334,000 | $6,422,000 |
| Other Current Liabilities | - | $16,060,000 | - | - |
| Non Current Deferred Liabilities | - | - | $1,526,000 | $53,207,000 |
| Total Tax Payable | - | - | $149,000 | $15,228,000 |
| Income Tax Payable | - | - | $149,000 | $15,228,000 |
| Non Current Deferred Taxes Liabilities | - | - | - | $3,253,000 |
| Equity | ||||
| Common Stock Equity | $765,276,000 | $1,150,385,000 | $1,590,236,000 | $2,077,963,000 |
| Total Equity Gross Minority Interest | $765,276,000 | $1,150,385,000 | $1,590,236,000 | $2,077,963,000 |
| Stockholders Equity | $765,276,000 | $1,150,385,000 | $1,590,236,000 | $2,077,963,000 |
| Gains Losses Not Affecting Retained Earnings | $-2,057,000 | $-1,717,000 | $-815,000 | $-9,122,000 |
| Other Equity Adjustments | $-2,057,000 | $-1,717,000 | $-815,000 | $-9,122,000 |
| Retained Earnings | $-1,197,771,000 | $-759,784,000 | $-237,824,000 | $377,237,000 |
| Other | ||||
| Ordinary Shares Number | $139,474,954 | $136,959,446 | $134,781,286 | $133,236,687 |
| Share Issued | $139,474,954 | $136,959,446 | $134,781,286 | $133,236,687 |
| Tangible Book Value | $740,489,000 | $1,125,328,000 | $1,550,707,000 | $2,028,302,000 |
| Invested Capital | $765,276,000 | $1,150,385,000 | $1,590,236,000 | $2,077,963,000 |
| Working Capital | $421,265,000 | $922,796,000 | $1,412,819,000 | $2,008,048,000 |
| Capital Lease Obligations | $97,852,000 | $97,891,000 | $124,540,000 | $127,974,000 |
| Total Capitalization | $765,276,000 | $1,150,385,000 | $1,590,236,000 | $2,077,963,000 |
| Additional Paid In Capital | $1,965,090,000 | $1,911,872,000 | $1,828,862,000 | $1,709,835,000 |
| Capital Stock | $14,000 | $14,000 | $13,000 | $13,000 |
| Common Stock | $14,000 | $14,000 | $13,000 | $13,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $89,054,000 | $90,139,000 | $111,673,000 | $123,837,000 |
| Current Deferred Revenue | $0 | $12,648,000 | $64,853,000 | $15,517,000 |
| Current Capital Lease Obligation | $8,798,000 | $7,752,000 | $12,867,000 | $4,137,000 |
| Current Accrued Expenses | $72,389,000 | $66,532,000 | $82,151,000 | $462,073,000 |
| Investments And Advances | $314,575,000 | $190,015,000 | $105,275,000 | $23,927,000 |
| Available For Sale Securities | $314,575,000 | $190,015,000 | $105,275,000 | $23,927,000 |
| Goodwill | $16,937,000 | $16,937,000 | $16,937,000 | $16,937,000 |
| Net PPE | $117,719,000 | $122,863,000 | $167,200,000 | $188,166,000 |
| Accumulated Depreciation | $-47,160,000 | $-36,785,000 | $-33,896,000 | $-20,743,000 |
| Gross PPE | $164,879,000 | $159,648,000 | $201,096,000 | $208,909,000 |
| Leases | $56,180,000 | $53,992,000 | $80,290,000 | $84,422,000 |
| Construction In Progress | $114,000 | $1,074,000 | $226,000 | $0 |
| Other Properties | $103,060,000 | $99,108,000 | $114,910,000 | $119,090,000 |
| Machinery Furniture Equipment | $5,525,000 | $5,474,000 | $5,670,000 | $5,397,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $234,830,000 | $682,401,000 | $1,280,833,000 | $1,553,409,000 |
| Non Current Deferred Revenue | - | - | $1,526,000 | $53,207,000 |
| Buildings And Improvements | - | - | - | - |
Fetched: 2026-07-17
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-396,613,000 | $-453,653,000 | $-800,358,000 | $1,595,247,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-391,781,000 | $-446,352,000 | $-778,785,000 | $1,663,253,000 |
| Cash Flow From Continuing Operating Activities | $-391,781,000 | $-446,352,000 | $-778,785,000 | $1,663,253,000 |
| Investing Activities | ||||
| Capital Expenditure | $-4,832,000 | $-7,301,000 | $-21,573,000 | $-68,006,000 |
| Investing Cash Flow | $310,371,000 | $499,367,000 | $164,629,000 | $-1,193,461,000 |
| Cash Flow From Continuing Investing Activities | $310,371,000 | $499,367,000 | $164,629,000 | $-1,193,461,000 |
| Financing Activities | ||||
| Financing Cash Flow | $3,785,000 | $4,388,000 | $7,480,000 | $34,761,000 |
| Cash Flow From Continuing Financing Activities | $3,785,000 | $4,388,000 | $7,480,000 | $34,761,000 |
| Net Other Financing Charges | $-361,000 | $-165,000 | $-287,000 | $-1,457,000 |
| Issuance Of Capital Stock | - | $0 | $0 | $28,462,000 |
| Net Common Stock Issuance | - | $0 | $0 | $28,462,000 |
| Common Stock Issuance | - | $0 | $0 | $28,462,000 |
| Repurchase Of Capital Stock | - | - | - | - |
| Net Preferred Stock Issuance | - | - | - | - |
| Preferred Stock Issuance | - | - | - | - |
| Other | ||||
| End Cash Position | $241,070,000 | $318,695,000 | $261,292,000 | $867,968,000 |
| Beginning Cash Position | $318,695,000 | $261,292,000 | $867,968,000 | $363,415,000 |
| Changes In Cash | $-77,625,000 | $57,403,000 | $-606,676,000 | $504,553,000 |
| Proceeds From Stock Option Exercised | $4,146,000 | $4,553,000 | $7,767,000 | $7,756,000 |
| Net Investment Purchase And Sale | $314,950,000 | $503,296,000 | $186,202,000 | $-1,125,455,000 |
| Sale Of Investment | $1,201,284,000 | $1,738,635,000 | $2,202,391,000 | $351,510,000 |
| Purchase Of Investment | $-886,334,000 | $-1,235,339,000 | $-2,016,189,000 | $-1,476,965,000 |
| Net PPE Purchase And Sale | $-4,579,000 | $-3,929,000 | $-21,573,000 | $-68,006,000 |
| Sale Of PPE | $253,000 | $3,372,000 | $0 | $0 |
| Purchase Of PPE | $-4,832,000 | $-7,301,000 | $-21,573,000 | $-68,006,000 |
| Change In Working Capital | $-22,447,000 | $-83,322,000 | $-332,709,000 | $665,367,000 |
| Change In Other Current Liabilities | $-7,368,000 | $-23,027,000 | $-13,046,000 | $-5,502,000 |
| Change In Other Current Assets | $-12,642,000 | $353,000 | $2,161,000 | $-11,795,000 |
| Change In Payables And Accrued Expense | $-4,512,000 | $-65,006,000 | $-358,111,000 | $-14,716,000 |
| Change In Accrued Expense | $-9,509,000 | $-64,018,000 | $-358,843,000 | $-15,513,000 |
| Change In Payable | $4,997,000 | $-988,000 | $732,000 | $797,000 |
| Change In Account Payable | $4,997,000 | $-988,000 | $732,000 | $797,000 |
| Change In Prepaid Assets | $2,075,000 | $4,358,000 | $36,287,000 | $-39,358,000 |
| Other Non Cash Items | $156,000 | $40,439,000 | $15,434,000 | $286,173,000 |
| Stock Based Compensation | $49,072,000 | $78,457,000 | $111,316,000 | $102,082,000 |
| Unrealized Gain Loss On Investment Securities | $-1,729,000 | $5,528,000 | $21,888,000 | $111,140,000 |
| Asset Impairment Charge | $0 | $14,550,000 | $9,658,000 | $0 |
| Amortization Of Securities | $9,474,000 | $5,397,000 | $-8,706,000 | $-8,943,000 |
| Depreciation Amortization Depletion | $11,680,000 | $14,559,000 | $19,451,000 | $6,783,000 |
| Depreciation And Amortization | $11,680,000 | $14,559,000 | $19,451,000 | $6,783,000 |
| Net Income From Continuing Operations | $-437,987,000 | $-521,960,000 | $-615,117,000 | $515,837,000 |
| Income Tax Paid Supplemental Data | - | $786,000 | $2,676,000 | $252,030,000 |
| Change In Other Working Capital | - | $-53,731,000 | $-2,345,000 | $-33,300,000 |
| Change In Receivables | - | $-6,513,000 | $-565,000 | $770,038,000 |
| Changes In Account Receivables | - | $-6,513,000 | $-565,000 | $770,038,000 |
| Deferred Tax | - | $-2,949,000 | $-1,063,000 | $-15,186,000 |
| Deferred Income Tax | - | $-2,949,000 | $-1,063,000 | $-15,186,000 |
| Pension And Employee Benefit Expense | - | $0 | - | - |
| Repayment Of Debt | - | - | $-287,000 | $-260,000 |
| Net Issuance Payments Of Debt | - | - | $-287,000 | $-260,000 |
| Net Long Term Debt Issuance | - | - | $-287,000 | $-260,000 |
| Long Term Debt Payments | - | - | $-287,000 | $-260,000 |
| Amortization Cash Flow | - | - | $531,000 | $532,000 |
| Amortization Of Intangibles | - | - | $531,000 | $532,000 |
| Depreciation | - | - | $18,920,000 | $6,251,000 |
| Issuance Of Debt | - | - | - | - |
| Common Stock Payments | - | - | - | - |
| Long Term Debt Issuance | - | - | - | - |
Fetched: 2026-07-17